ABSTRACT
Magnetic Resonance Imaging (MRI) has huge potential for radiotherapy treatment simulation, tumor characterization, and treatment response assessment. e so tissue visualization of MRI is superior to that of other imaging modalities for almost all tumor and normal tissues. As an example, for prostate tumors, MRI is already the gold standard for delineation of the prostate (Fütterer et al. 2008), while dynamic contrast enhanced imaging (DCE-MRI) and diusion weighted imaging (DWI) are used to determine the exact tumor position inside the prostate (Groenendaal et al. 2010; Jackson et al. 2009; Korporaal et al. 2010). (High eld) MR spectroscopy is investigated for tumor characterization (Kurhanewicz and Vigneron 2008; Klomp et al. 2009). Lymph node involvement can be judged and tracked by using USPIOs (Barentsz et al. 2007) in combination with DWIBS (Klerkx et al. 2009). Recently, it was found that both DCE-MRI and DWI are very well suited to determine whether and where tumors recur inside the prostate making focal salvage therapy possible (Moman et al. 2010).
